FDA panel largely opposes expanding use of Lilly, Boehringer's SGLT2 inhibitor to type 1 diabetics
Last week, Eli Lilly and partner Boehringer Ingelheim rejigged the terms of their 2011 diabetes pact that nurtured the development of their blockbuster Jardiance …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
